Top 5 Key Players companies in Multiple sklerose by Highest Patent Value in the Australia in 2022 – Discovery

Free Trial

The Multiple sklerose top 5 is Discovery PatSnap’ annual ranking of the top 5 Highest Patent Value Multiple sklerose Key Players in the Australia. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.

1	CSL Ltd.	New South Wales, Australia	Health care,Clinical trial,Influenza vaccine, ...[+2]	Avg patent value: 4.34 M
2	Cellestis Pty Ltd.	Victoria, Australia	Immunohistochemistry,Medicine,Health care, ...[+2]	Avg patent value: 3.79 M
3	Antisense Therapeutics Ltd.	Victoria, Australia	Pharmacy and Therapeutics,Medicine,CD49d, ...[+2]	Avg patent value: 3.28 M
4	Immune System Therapeutics Ltd.	New South Wales, Australia	Medicine,Blood cancers,Blood Disorder, ...[+2]	Avg patent value: 220,000
5	STARTUP HaemaLogiX Pty Ltd.	New South Wales, Australia	Antigen,Biology,Health care, ...[+2]	Avg patent value: 0

Page generation time: Jul 26 2025

Top 5 Key Players companies in Multiple sklerose
by Highest Patent Value in the Australia in 2022

Key Players

Fast-growings

Startups & Unicorns

New Entrants

2022

2021

2020

2019

2018

Global

China

Japan

India

United States

Switzerland

United Kingdom

Belgium

Denmark

Netherlands

Israel

Canada

France

Germany

Spain

Italy

Australia

South Korea

Sweden

Most Patent Filings

Highest Patent Value

Who we serve

Why Discovery

Social media

Try Discovery